Table 3.
Clinical parameters of the DLBCL patients of the study group.
| Clinical Parameters | All Group (n = 73) |
MIR-34A | MIR-34B/C | MIR-203 | MIR-129-2 | ||||
|---|---|---|---|---|---|---|---|---|---|
| M (n = 20) |
U (n = 53) |
M (n = 45) |
U (n = 28) |
M (n = 48) |
UM (n = 25) |
M (n = 49) |
UM (n = 24) |
||
| Sex (p-value) | 0.100 | 0.698 | 0.101 | 0.562 | |||||
| M | 36 | 13 | 23 | 23 | 13 | 27 | 9 | 23 | 13 |
| F | 37 | 7 | 30 | 22 | 15 | 21 | 16 | 26 | 11 |
| Age (p-value) | 0.051 | 0.241 | 0.900 | 0.950 | |||||
| ≤60 years | 46 | 9 | 37 | 26 | 20 | 30 | 16 | 31 | 15 |
| >60 years | 27 | 11 | 16 | 19 | 8 | 18 | 9 | 18 | 9 |
| ECOG score (p-value) | 0.758 | 0.034 | 0.617 | 0.457 | |||||
| ≤1 | 35 | 9 | 26 | 26 | 9 | 22 | 13 | 22 | 13 |
| ≥2 | 38 | 11 | 27 | 19 | 19 | 26 | 12 | 27 | 11 |
| Stage (p-value) | 0.513 | 0.068 | 0.095 | 0.105 | |||||
| I | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 |
| II | 4 | 1 | 3 | 4 | 0 | 4 | 0 | 4 | 0 |
| III | 11 | 2 | 9 | 9 | 2 | 9 | 2 | 8 | 3 |
| IV | 57 | 16 | 41 | 31 | 26 | 34 | 23 | 36 | 21 |
| Extranodal involvement (p-value) | 0.279 | 0.509 | 0.898 | 0.703 | |||||
| ≥2 sites | 14 | 5 | 9 | 9 | 5 | 9 | 5 | 10 | 4 |
| Bone marrow involvement (p-value) | 0.832 | 0.785 | 0.492 | 0.156 | |||||
| Yes | 17 | 5 | 12 | 10 | 7 | 10 | 7 | 9 | 8 |
| LDH level (p-value) | 0.064 | 0.305 | 0.202 | 0.270 | |||||
| >450 IU/L | 42 | 15 | 27 | 28 | 14 | 23 | 19 | 26 | 16 |
| IPI score (p-value) | 0.002 | 0.667 | 0.639 | 0.435 | |||||
| 0–2 | 29 | 2 | 27 | 17 | 12 | 20 | 9 | 21 | 8 |
| 3–5 | 44 | 18 | 26 | 28 | 16 | 28 | 16 | 28 | 16 |
Keys: ECOG—Eastern Cooperative Oncology Group, IPI—International Prognostic Index, LDH—Lactate dehydrogenase.